pharma news

News

Kidney biotech R1's $78m debut, and other biofinancings

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

News

FDA approves higher Wegovy dose via 4th priority voucher

The US FDA has approved a fourth product via its new National Priority Voucher Programme - a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy.

News

Lilly's triple agonist retatrutide passes diabetes test

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.

News

Black and white letters spelling out 'Mental Health Matters' on a grey background

Precision psychiatry push starts in Europe

As geopolitical tensions ratchet up around the world, an initiative has been launched to drive improvements in diagnostic accuracy and precision care.

News

Generic semaglutide in India, and other weight-loss news

Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.

News

Alfasigma claims early FDA nod for ex-GSK liver drug

Alfasigma has claimed the first approval, in the US, for linerixibat, a drug for liver disease PBC licensed from GSK for $690m a few days ago.

Kidney biotech R1's $78m debut, and other biofinancings

FDA approves higher Wegovy dose via 4th priority voucher

Lilly's triple agonist retatrutide passes diabetes test

Precision psychiatry push starts in Europe

Generic semaglutide in India, and other weight-loss news

Alfasigma claims early FDA nod for ex-GSK liver drug

EMA seeks input on virtual alternative to animal test

Using AI-driven synthetic personas to take your insights fur...

pharma news

Editor's Picks